Jie Wu^1,2, Zhewei Zhang^1,2, Kit Ying Chan^1,2, Tat San Lau^1,2,*, Chi Chiu Wang^1,2,3,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083359 - 13 August 2026

Abstract Ovarian cancer is the most lethal gynecological malignancy, with most patients diagnosed at an advanced stage and eventually relapsed after post-platinum-taxane chemotherapy. High intratumoral heterogeneity, extensive peritoneal dissemination, and acquired chemoresistance continue to restrict the clinical benefits of current therapeutic strategies. Increasing evidence indicates that ovarian cancer stem cells (OCSCs), a rare but highly plastic subpopulation characterized by self-renewal, multilineage differentiation, quiescence, tumor-initiating capacity, and intrinsic stress tolerance, play pivotal roles in tumor initiation, metastasis, recurrence, and therapeutic resistance. In this review, we systematically summarize current knowledge regarding the identification and functional characterization of OCSCs More >

Zhiqing Hu¹, Lisha Ma², Weili Zhu^2,*

BIOCELL, Vol.50, No.8, 2026, DOI:10.32604/biocell.2026.077860 - 27 July 2026

Abstract Ovarian cancer (OC) is the most lethal gynecologic malignancy. The current first-line treatment still relies primarily on cisplatin-based chemotherapy, yet cisplatin resistance strongly predicts poor patient prognosis. Cuproptosis is a newly identified cell death modality driven by copper overload and impaired mitochondrial respiration. This review outlines the core molecular mechanisms of cuproptosis and examines its complex association with cisplatin resistance in ovarian cancer. Their interplay involves shared transport systems. In cisplatin-resistant ovarian cancer cells, copper influx transporter Copper Transporter 1 (CTR1) downregulation and efflux transporter ATPase copper transporting alpha/beta polypeptide (ATP7A/B) upregulation reduce the intracellular… More >

Lorenzo Gasperoni^1,*, Luna Del Bono², Alberto Farolfi³, Andrea Messori^4,5, Vera Damuzzo^5,6

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.077700 - 16 June 2026

Abstract Background: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are established maintenance treatments in ovarian cancer, but comparative efficacy across genetic profiles and relapse risk categories remains unclear. The aim of this study was to compare the efficacy of different PARPi as maintenance therapy in ovarian cancer across genetic profiles and relapse risk categories using reconstructed individual patient data (IPD) from randomized trials (RCTs). Methods: IPD were reconstructed using the IPDfromKM method from published Kaplan-Meier curves of RCTs stratified by clinical risk subgroup. Progression-free survival (PFS) was the primary endpoint. Three comparisons were performed: Breast Cancer gene (BRCA)+… More >

Yan Zhu^1,#, Bin Guan^1,#, Wencai Guan¹, Jihong Zhang¹, Shiyu Wang¹, Jimin Shi¹, Wei Fan¹, Qi Lu^2,3, Lingyun Zhang^4,5,*, Guoxiong Xu^1,2,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.075241 - 22 April 2026

Abstract Background: Ovarian cancer poses the greatest threat to survival among gynecologic cancers in women. Long non-coding RNAs (lncRNAs) have emerged as critical regulators in oncogenesis. The current study aimed to elucidate the function and regulatory mechanism of lncRNA KRT7-AS in ovarian cancer. Methods: The clinical significance of KRT7-AS was evaluated through bioinformatics analysis of data from public repositories. KRT7-AS expression was examined by RT-qPCR and fluorescence in situ hybridization. The function analyses were conducted using assays for cell proliferation, migration, invasion, wound healing, and colony formation. Assessment of cell cycle and apoptosis was performed using flow… More >

Carlo Ronsini^1,*, Giuseppe Cucinella¹, Maria Cristina Solazzo¹, Mariano Catello Di Donna¹, Cono Scaffa¹, Stefano Cianci², Manuela Ludovisi³, Sandro Pignata⁴, Vito Chiantera¹

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074934 - 22 April 2026

Abstract Background: The optimal sequencing of surgery and chemotherapy in advanced epithelial ovarian cancer remains debated. While primary debulking surgery (PDS) has been considered the standard approach, recent randomized trials have questioned its survival advantage over neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The study aimed to systematically evaluate phase III randomized controlled trials comparing PDS and NACT. Methods: Following PRISMA guidelines (PROSPERO ID 1169057), PubMed and Scopus were systematically searched in October 2025 for phase III randomized clinical trials evaluating cytoreductive strategies in ovarian carcinoma. Only full-text English studies reporting overall survival (OS)… More >

Chia-Chia Chao¹, Cheng-Yao Lin^2,3,4, Po-Chun Chen^5,6,7, Wen-Tsung Huang², Teng-Song Weng⁸, Sheng-Yen Hsiao^2,9,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074383 - 22 April 2026

Abstract Background: Partial epithelial–mesenchymal transition (p-EMT) is a dynamic cellular state associated with metastasis and adverse outcomes in multiple cancers, but its prognostic significance in ovarian cancer remains unclear. This study aimed to develop and validate an ovarian cancer–specific transcriptomic signature based on p-EMT–related genes, and to determine whether this signature can improve prognostic stratification and overall survival prediction across independent cohorts. Methods: A pan-cancer p-EMT gene set was curated from ten published studies. Using transcriptomic and clinical data from TCGA-OV (n = 488), a six-gene p-EMT signature was developed via LASSO regression to generate a… More >

Anna PawłOwska-ŁAchut^*, Dorota Suszczyk, Iwona Wertel

BIOCELL, Vol.50, No.4, 2026, DOI:10.32604/biocell.2025.072104 - 21 April 2026

Abstract Ovarian cancer (OC) remains the most lethal gynecological malignancy, and it is characterized by high heterogeneity, early metastatic dissemination, and frequent recurrence within 12–18 months after primary therapy. Despite progress in clinical management and drug development, the mortality rate remains high, and the biological drivers of OC aggressiveness are not fully understood. A major contributor to therapeutic resistance and disease progression is the ovarian tumor microenvironment (TME), which supports tumor growth and immune evasion. Its complexity poses significant challenges to the development of effective therapies. Current treatments, especially in advanced or recurrent stages, have limited… More >

Daniyal Asif^1,*, Nabil Kerdid², Muhammad Shoaib Arif³, Mairaj Bibi⁴

CMES-Computer Modeling in Engineering & Sciences, Vol.146, No.3, 2026, DOI:10.32604/cmes.2026.077334 - 30 March 2026

Abstract Ovarian cancer (OC) is one of the leading causes of death related to gynecological cancer, with the main difficulty of its early diagnosis and a heterogeneous nature of tumor biomarkers. Machine learning (ML) has the potential to process complex datasets and support decision-making in OC diagnosis. Nevertheless, traditional ML models tend to be biased, overfitting, noisy, and less generalized. Moreover, their black-box nature reduces interpretability and limits their practical clinical applicability. In this study, we introduce an explainable ensemble learning (EL) model, TreeX-Stack, based on a stacking architecture that employs tree-based learners such as Decision… More >

Gwan Hee Han^1,2,#, Hee Yun^3,#, Joon-Yong Chung⁴, Jae-Hoon Kim^3,5,6, Hanbyoul Cho^3,5,6,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.072105 - 24 February 2026

Abstract Objectives: Phosphodiesterase 1A (PDE1A) regulates intracellular cyclic nucleotide signaling and has been implicated in tumor progression, but its clinical relevance and functional role in epithelial ovarian cancer (EOC), particularly in relation to the response to platinum remain unclear. This study aimed to evaluate the clinical significance of PDE1A in EOG and to clarify its functional role in tumor progression and response to platinum-based chemotherapy. Methods: PDE1A mRNA and protein levels were analyzed using public databases, RNA sequencing, and immunohistochemistry. Correlations between PDE1A expression, clinicopathological features, and prognosis were assessed. Functional roles were investigated in ovarian… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077268 - 30 December 2025

Abstract This article has no abstract. More >